SCHEMBL13128981

SCHEMBL13128981

CC(C)=NNc1ccc(N=O)cc1S(=O)(=O)Nc1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ PTK2B Q14289 2/20 0.42
▸ GRM4 Q14833 2/20 0.41
▸ LMNA P02545 4/20 0.41
▸ KMT2A Q03164 6/20 0.39
▸ TSHR P16473 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ MAPT P10636 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ BRD4 O60885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741012 0.81 CRHBP (0.53) ALDH1A1SMN1; SMN2LMNAKMT2AKDM4E
SCHEMBL13165623 0.73 SMN1; SMN2 (0.43) SMN1; SMN2LMNAKMT2AKDM4EMEN1
SCHEMBL13128959 0.68 KDM4E (0.54) ALDH1A1SMN1; SMN2GRM4LMNAKMT2A
SCHEMBL2740997 0.67 MCL1 (0.62) SMN1; SMN2PTK2BGRM4KMT2ATSHR
SCHEMBL2741004 0.66 CRHBP (0.51) ALDH1A1SMN1; SMN2LMNAKMT2AMEN1
SCHEMBL2740999 0.65 MAPT (0.49) ALDH1A1SMN1; SMN2PTK2BLMNAKMT2A
SCHEMBL14160326 0.65 MEN1 (0.46) ALDH1A1SMN1; SMN2PTK2BLMNAKMT2A
SCHEMBL14161620 0.64 POLB (0.60) SMN1; SMN2PTK2BKMT2ATSHRKDM4E
SCHEMBL3817707 0.63 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2PTK2BGRM4LMNA
SCHEMBL2740996 0.62 PTGES2 (0.56) SMN1; SMN2PTK2BKMT2ATSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 ALDH1A1 3484/4885SMN1; SMN2 2187/4885PTK2B 2888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback